Italy: EU Proposal For A Regulation On Medical Devices: Impact On The Perceived European Advantage In Marketing Novel Devices

Last Updated: 29 July 2013
Article by Flavio Monfrini

Italy Legal Focus

The European legislative framework for the marketing and surveillance of medical devices has recently come under public scrutiny following the PIP breast implants scandal. While such scandal is believed to be solely caused by specific flaws in market surveillance, the European system in its entirety – and in particular the absence of a centralized pre-market approval – has come under criticism.

On June 14, 2012, with the adoption of the so called "PIP resolution", the European Parliament called on the Commission – inter alia – to introduce, in addition to strengthened post-market surveillance measures, a pre-market authorization system, at least for devices falling in the higher-risk classes (IIb and III). This came as sweeping news in the European medical device diatribe, and encountered the strong opposition of the industry, as well as a cold welcome from the European Commission itself.

While the FDA, which manages pre-market approval for all medical devices placed on the US market, stepped in the debate accusing the European system to disregard the best interest of patients and their safety (while not providing earlier market availability due to lengthy reimbursement procedures), European industry representatives argued that introducing a pre-market authorization would stifle innovation, delay access to new devices and worsen the overall quality of healthcare for European patients.

Here follows a short account of the new provisions of the Proposal that are more likely to affect the timing for marketing of new devices in Europe, without doubt the most recognized advantage of the European system so far as compared to the lengthy FDA-managed procedure.

THE NEW MEDICAL DEVICE COORDINATION GROUP. The Proposal aims at establishing a group of experts, the Medical Device Coordination Group ("MDCG"), somehow similar to an advisory board, which is meant to bring together the European Commission and experts from each member states. Such MDCG would essentially be entrusted with coordination and management tasks, thus providing a centralized support framework for the exchange of information, monitoring of Notified Bodies and conduct of clinical investigations. The industry welcomed this new entity, which is expected to counterbalance the decentralized approach maintained in the Proposal and will help to achieve a better management of the whole European system.

SCRUTINY PROCEDURE. While the establishment of the new MDCG itself triggered positive reactions from the industry, its role in the brand new scrutiny procedure is at best controversial. Such procedure, in fact, requires Notified Bodies to notify the European Commission of any new applications for conformity assessment for high-risk class III devices, and enables the MDCG to review the Notified Body's assessment and submit comments based on health and scientific reasons. This scrutiny procedure has been harshly criticized as de facto creating a pre-market approval mechanism, entailing extended deadlines and increasing bureaucratic formalities and requirements on Notified Bodies during the conformity assessment. As such, it has been pointed out that the procedure itself will not increase the safety for patients, but instead will prevent life-saving products from promptly being available to European citizens.

IMPACT OF THE NEW PROVISIONS ON CLINICAL TRIALS. The Proposal also impacts the procedures and requirements for the conduct of clinical trials and devices, with a potential impact on the time-to-market for new devices. In particular, it has been pointed out that potential delays by the Commission to adopt any required implementing measures may potentially damage manufacturers and cause delays in the pre-market phase. In fact, clinical trials usually require early planning and preparation, which may both be impaired by an unclear regulatory framework. However, it should also be noted that the industry welcomed the new provisions on clinical investigations as providing a clearer European framework.

POTENTIAL IMPACT FOR COMBINATION PRODUCTS. The Proposal sets forth new requirements for the marketing of combination products, i.e., a combination of medicinal products and medical devices. In particular, it is provided that the European Medicine Agency or national medicine agencies in each Member State may review the conformity assessment issued by the Notified Body and independently assess the conclusions contained therein, thus in fact being entitled to veto the access to market of combination products.

POTENTIAL IMPACT FOR ACCESSORIES. Lastly,a new and broader definition of accessories to medical devices is provided in the Proposal, thus including all devices that not only enable, but also "assist" the device to be used in accordance with its intended purpose. While the outcome of this new change is still to be assessed, the new language may subject whole new categories of accessories to European regulations, thus potentially delaying the marketing of such devices.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions